Sites and overall 5-year survival rates in patients with gastroenteropancreatic NETs in the USA (from the SEER Programme), Norway (from the NRC) and England and Wales12–14 37
| Site | Percentage surviving | ||||
| SEER data (n=17 312) | England and Wales | ||||
| Black patients | White patients | NRC data (n=2013) | Well-differentiated tumours | Small cell tumours* | |
| Lung | 36 | 48 | 54 | – | – |
| Stomach | 56 | 64 | 45 | 52 | 18 |
| Small intestine | 64 | 70 | 59 | 59 | 27 |
| Pancreas | 27 | 35 | 43 | 39 | 17 |
| Appendix | 70 | 79 | 74 | – | – |
| Colon | 61 | 53 | 41 | 65 | 27 |
| Rectum | 85 | 88 | 74 | – | – |
↵* Data are for 1-year survival.
NET, neuroendocrine tumour; NRC, Norwegian Registry of Cancer; SEER, Surveillance, Epidemiology and End Results.